Literature DB >> 35819545

Boswellic acids, as novel inhibitor targeting peptidoglycan biosynthetic enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) in Escherichia coli.

Diksha Raina1,2,3, Farrah Gul Khan1, Harshita Tiwari4,3, Payare L Sangwan5, Amit Nargotra4,3, Vinod Kumar2,3, Inshad Ali Khan6,7, Saurabh Saran8,9.   

Abstract

UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is an essential cytosolic enzyme in the biosynthesis of peptidoglycan. It becomes a potential bacterial target for screening promising antibacterial compounds as it is associated with the early phases of peptidoglycan production. MurA enzyme is conserved and necessary for bacterial viability with no mammalian homolog, which is a well-proven therapeutic research target. The present study reports the natural compounds from Boswellia serrata targeting the MurA enzyme. The identified inhibitors against MurA Escherichia coli (E. coli): β-boswellic acid (IC50 33.65 µM), Acetyl-β-boswellic acid (IC50 30.17 µM), and Acetyl-11-keto-β-boswellic acid (IC50 37.67 µM). Inhibitors showed a fourfold decrease in IC50 values on pre-incubation with substrate-UDP-N-acetyl-glucosamine (UDP-GlcNAc). Mode-of-inhibition studies revealed their uncompetitive nature with both the substrates. Although these boswellic acids have been explored for their pharmacological potential, this is the first study reporting these compounds' E. coli MurA inhibiting potential.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Boswellic acids; Docking; MurA; Natural compounds; Peptidoglycan

Mesh:

Substances:

Year:  2022        PMID: 35819545     DOI: 10.1007/s00203-022-03066-7

Source DB:  PubMed          Journal:  Arch Microbiol        ISSN: 0302-8933            Impact factor:   2.667


  27 in total

1.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

Review 2.  Structure and function of the Mur enzymes: development of novel inhibitors.

Authors:  Ahmed El Zoeiby; François Sanschagrin; Roger C Levesque
Journal:  Mol Microbiol       Date:  2003-01       Impact factor: 3.501

3.  Structure-activity relationships of tulipalines, tuliposides, and related compounds as inhibitors of MurA.

Authors:  Thomas Mendgen; Therese Scholz; Christian D Klein
Journal:  Bioorg Med Chem Lett       Date:  2010-08-05       Impact factor: 2.823

4.  The amino analogue of β-boswellic acid efficiently attenuates the release of pro-inflammatory mediators than its parent compound through the suppression of NF-κB/IκBα signalling axis.

Authors:  Shilpa Gupta; Aitizaz Ul Ahsan; Abubakar Wani; Vidushi Khajuria; Lone A Nazir; Simmi Sharma; Asha Bhagat; Parduman Raj Sharma; Subhash Bhardwaj; Kaiser J Peerzada; Bhahwal Ali Shah; Zabeer Ahmed
Journal:  Cytokine       Date:  2017-12-08       Impact factor: 3.861

Review 5.  Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data.

Authors:  Mona Abdel-Tawab; Oliver Werz; Manfred Schubert-Zsilavecz
Journal:  Clin Pharmacokinet       Date:  2011-06       Impact factor: 6.447

6.  Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin.

Authors:  D H Kim; W J Lees; K E Kempsell; W S Lane; K Duncan; C T Walsh
Journal:  Biochemistry       Date:  1996-04-16       Impact factor: 3.162

7.  Identification and characterization of new inhibitors of the Escherichia coli MurA enzyme.

Authors:  E Z Baum; D A Montenegro; L Licata; I Turchi; G C Webb; B D Foleno; K Bush
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Metabolism of boswellic acids in vitro and in vivo.

Authors:  Phillip Krüger; Rambod Daneshfar; Gunter P Eckert; Jochen Klein; Dietrich A Volmer; Ute Bahr; Walter E Müller; Michael Karas; Manfred Schubert-Zsilavecz; Mona Abdel-Tawab
Journal:  Drug Metab Dispos       Date:  2008-03-20       Impact factor: 3.922

9.  Extended-spectrum β-lactamase-producing Escherichia coli in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study.

Authors:  Michaela J Day; Katie L Hopkins; David W Wareham; Mark A Toleman; Nicola Elviss; Luke Randall; Christopher Teale; Paul Cleary; Camilla Wiuff; Michel Doumith; Matthew J Ellington; Neil Woodford; David M Livermore
Journal:  Lancet Infect Dis       Date:  2019-10-22       Impact factor: 25.071

Review 10.  Escherichia coli β-Lactamases: What Really Matters.

Authors:  Priyanka Bajaj; Nambram S Singh; Jugsharan S Virdi
Journal:  Front Microbiol       Date:  2016-03-30       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.